Company profile

Solianis Holding AG is a medical devices company developing a non-invasive Continuous Glucose Monitor (CGM) for self-monitoring patients with diabetes, within the broader range of physiological monitoring.

In a number of trials, conducted in cooperation with the University Hospital Zurich since May 2006, Solianis has shown that its multisensor platform reliably tracks glucose changes in patients with diabetes as well as healthy subjects. In these trials, the subjects have gone through glucose challenges under various conditions designed to test the impact of the additional effects, thus simulating real life conditions.

In a breakthrough clinical trial (“Outpatient study”), finalized in November 2008, the applicability of the platform was further demonstrated in an outpatient setting, i.e. patients are wearing a first configuration of the future device in their daily life. First results with 16 patients and over 200 test days look promising.